Loading data for NGNE — first visit, this takes a few seconds.
Neurogene Inc. (NGNE)
NasdaqGM: NGNE
· Real-Time Price · USD
36.58
-1.28 (-3.38%)
At close: Aug 31, 2026, 5:43 PM
The price, the headline numbers and the latest news, in one place.
Neurogene Inc. (NGNE) Stock Price, Analysis & Data
-3.38% (1D)
No data available
| Bid | 25.99 |
| Market Cap | 720.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -111.11M |
| 1.95 | |
| -5.04 | |
| n/a | |
| -6.95 | |
| P/B (ttm) | 2.62 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 12, 2026 |
| Ask | 44.63 |
| Volume | 132,795 |
| Avg. Volume (20D) | 232,807 |
| Open | 37.68 |
| Previous Close | 37.86 |
| Day's Range | 36.31 - 37.93 |
| 52-Week Range | 15.93 - 43.66 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NGNE
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 7, 2014
Employees 131
Stock Exchange NasdaqGM
Ticker Symbol NGNE
Website https://www.neurogene.com
Financial Performance
In 2025, Neurogene's revenue was 0, a decrease of -100% compared to the previous year's 925K. Earnings were -90.35M, an increase of 20.24%.
Financial StatementsEarnings Surprise
Neurogene has released their quarterly earnings on Aug 11, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -1.53 misses estimates by -0.16, with -41.67% YoY decline.
Neurogene Inc. is scheduled to release its earnings on Nov 12, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2